A Pilot Study on the Combination Treatment of Reduced-Fluence Photodynamic Therapy, Intravitreal Ranibizumab, Intravitreal Dexamethasone and Oral Minocycline for Neovascular Age-Related Macular Degeneration

Changes in Aqueous Vascular Endothelial Growth Factor and Pigment Epithelium-derived Factor after Ranibizumab Alone or Combined with Verteporfin for Exudative Age-related Macular Degeneration

(2009) Jae Kyoun Ahn et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: the VIA study

(2009) M. J. Potter et al.   BRITISH JOURNAL OF OPHTHALMOLOGY

SAME-DAY TRIPLE THERAPY WITH PHOTODYNAMIC THERAPY, INTRAVITREAL DEXAMETHASONE, AND BEVACIZUMAB IN WET AGE-RELATED MACULAR DEGENERATION

(2009) SOPHIE J. BAKRI et al.   RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES

Ranibizumab Combined With Verteporfin Photodynamic Therapy in Neovascular Age-related Macular Degeneration (FOCUS): Year 2 Results

(2008) Andrew N. Antoszyk et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

Combination of verteporfin photodynamic therapy and ranibizumab: effects on retinal anatomy, choroidal perfusion and visual function in the protect study

(2008) C G Kiss et al.   BRITISH JOURNAL OF OPHTHALMOLOGY

Same-day administration of verteporfin and ranibizumab 0.5 mg in patients with choroidal neovascularisation due to age-related macular degeneration

(2008) U Schmidt-Erfurth et al.   BRITISH JOURNAL OF OPHTHALMOLOGY

Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study

(2008) David M. Brown et al.   OPHTHALMOLOGY